OWKIN
3.7.2024 09:01:37 CEST | Business Wire | Press release
Owkin, the first end-to-end AI-biotech unicorn that provides best-in-class AI-driven precision drug discovery, development and diagnostics, has announced its expansion into the DACH region (Germany, Austria and Switzerland) following partnerships with nine of the top centers in the region, including Charité – Universitätsmedizin Berlin, Centre Hospitalier Universitaire Vaudois (CHUV), Universitätsspital Basel, Technische Universität München (TUM), Uniklinikum Erlangen, Universitätsklinikum Leipzig, Inselspital Bern, Universitätsklinik Mannheim-Heidelberg and Medizinische Universität Wien. These collaborations signify unparalleled representation of patient populations, representing 24% of all outpatient cases and 15% of the total patients in the DACH region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240703400559/en/
Guillaume Bézie, Director of Partnerships Western Europe: “The Western Europe network covering France, Benelux and DACH represents the largest pool of centres for Owkin. Partnering with top academic institutions is an inevitable asset for our expansion strategy, and we are delighted to showcase the ability to significantly increase our footprint in the DACH region. By capturing the diverse landscape of human health, we empower our AI to better address the unique needs of all individuals. With our partners, we are fully committed to accelerate the secondary use of multimodal patient data for the purpose of giving the right treatment for each patient.”
By analyzing vast datasets and identifying complex patterns across the nine hospitals, Owkin will use its AI engines and diagnostic tools to improve patient outcomes in Prostate Cancer, Muscle Invasive Bladder Cancer (MIBC), and Cardiovascular Disease (CVD). This will enable researchers to discover novel biomarkers, predict treatment responses, and develop more effective therapies tailored to individual patients.
- BiomarkerPlus (Outcome prediction): Owkin will work with Inselspital Bern, Technische Universität München (TUM) and Universitätsspital Basel to analyze multimodal patient data to identify which early-stage prostate cancer patients are most likely to fail primary curative treatment and ultimately progress to more severe disease and anticipate if they may benefit from a different management strategy. Owkin is also partnering with Uniklinikum Erlangen (UKER) on MIBC to analyze H&E slides to detect FGFR3 mutations.
- TargetMatch (Target discovery): In partnership with Medizinische Fakultät Mannheim der Ruprecht-Karls-Universität and Medizinische Universität Wien, Owkin will access a high-quality multimodal dataset, including digitized histology and RNA-seq, to better understand the response to treatment for neoadjuvant chemotherapy and to identify new targets and treatment strategies in MIBC.
- TrialPlus (Clinical trial optimization): Owkin’s partnership with Universitätsklinikum Leipzig aims to use machine learning techniques to enhance clinical trial design for CVD.
- AI Diagnostics (MSIntuit® CRC): To further improve Owkin’s first CE-IVD-approved MSI pre-screening tool MSIntuit® CRC, Owkin will work in close collaboration with Uniklinikum Erlangen (UKER) to validate our upgraded MSIntuit CRC V2 on more diverse cohorts.
In addition to advancing research towards more personalized treatment strategies for patients with prostate cancer, MIBC and CVD, Owkin has also expanded its MOSAIC network, a global initiative to build the world’s largest spatial omics dataset in oncology with 7,000 patient samples across 7 cancer indications, bringing on Uniklinikum Erlangen, Charité – Universitätsmedizin Berlin and Centre Hospitalier Universitaire Vaudois (CHUV) to accelerate research across numerous therapeutic areas.
Dr. Philipp Mann, Principal Partnerships Manager Switzerland, Germany and Austria (DACH) said: “The healthcare system across the DACH region is an invaluable asset because it offers an extensive repository of reliable, comprehensive health data that can guide drug discovery and development strategies. The collaboration between Owkin and these institutions enhances the use of this data, driving innovation and fast-tracking medical advancements. With the combined expertise of these partners, the data can be transformed into actionable insights used to revolutionize patient care and improve health outcomes.”
About Owkin
Owkin is the first end-to-end AI-biotech unicorn on a mission to understand complex biology and derive new multimodal biomarkers through AI. We identify precision therapeutics, de-risk and accelerate clinical trials and develop diagnostics using AI trained on world-class patient data through privacy-enhancing federated technologies. We merge wet lab experiments with advanced AI techniques to create a powerful feedback loop for accelerated discovery and innovation in oncology, cardiovascular, immunity and inflammation. Owkin also founded MOSAIC, the world’s largest spatial multi-omics atlas for cancer research. Owkin has raised over $300 million through investments from leading biopharma companies, including Sanofi and BMS, and venture funds like Fidelity, GV and Bpifrance, among others.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240703400559/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 17:00:00 CET | Press release
Canada becomes the 25th Allied nation to back the NATO Innovation Fund, gaining access to €1.1 billion in mission-aligned capital and a co-investor network spanning the Alliance Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the amb
Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 15:30:00 CET | Press release
Independent evaluation of Persona's Android SDK confirms defenses against deepfakes and other injected media at the top level of the first standard Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result
Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 22:30:00 CET | Press release
Proposed facilitation of China Resources’ exit from Oatly requires a tender offer because of Swedish law requirements Verlinvest recommends that Oatly shareholders and holders of ADSs do not tender their shares or ADSs. Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement
Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press release
With Picsart Platform, developers can build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. Key Takeaways One bundle, four ways to build: the API, the CLI, a playground to test models, and Picsart Media Studio, an MCP server that works with compatible AI assistants. One integration for image, video, audio and text generation from 250+ models across 30+ providers, with the freedom to switch models as a product evolves. Self-serve users pay per generation at competitive, published rates. Developers get access to Picsart's proprietary editing models, like Enhance and background removal, which are only available on Picsart Platform. Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 mil
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release
The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
